GSK, Harvard ink stem cell research pact

In another instance of the industry teaming up with academia, GlaxoSmithKline and Harvard Stem Cell Institute (HSCI) announced that they have signed a five-year, $25 million pact to research and possibly develop stem cell drugs. GSK will fund HSCI's research in several areas, including neuroscience, heart disease, cancer, diabetes, musculoskeletal diseases and obesity. The company will also fund an annual grant, which supports early stage research in stem cell biology.

Part of the draw for GSK, apparently, is the concentration of skilled biotech workers in the Boston area. "We have carefully chosen the Boston biomedical community to collaborate with on this important venture. It has the highest concentration of leading stem cell scientists, and the Harvard Stem Cell Institute is the epicenter of that community," said Patrick Vallance, GSK's drug discovery chief. The Boston Globe notes that the deal is one of the largest stem cell investments ever made by a Big Pharma company.

- see this GSK release
- read the Boston Globe's report

Suggested Articles

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.

Since Takeda bought out Shire, it’s lost a number of high-ranking research execs from the Irish rare disease biotech; it’s also losing one of its own.

Just a few months after a series B-plus worth $75 million, U.S.-China biotech Harbour BioMed has nabbed a major $102.8 million series C.